Traditional Chinese medicine split prescription composition for warming kidney, strengthening marrow, reinforcing qi, nourishing yin, generating blood and stopping bleeding and preparation method thereof

Abstract

The invention relates to a traditional Chinese medicine split formula composition for warming kidney, strengthening marrow, reinforcing qi, nourishing yin, generating blood and stopping bleeding and a preparation method thereof. The traditional Chinese medicine composition is prepared from four traditional Chinese medicinal materials, namely melanterite, American ginseng, sea horse and cinnamon. According to the formula of the traditional Chinese medicine composition, on the basis of a compound melanterite pill formula, the formula of the compound melanterite pill is split, and the optimal formula is obtained through a large number of clinical pharmacodynamic tests. The medicine has the effects of warming kidney, strengthening marrow, reinforcing qi, nourishing yin, generating blood and stopping bleeding; the traditional Chinese medicine composition is mainly used for treating aplastic anemia, leucopenia, thrombocytopenia, myelodysplastic syndrome, bone marrow injury caused by radiotherapy and chemotherapy, kidney-yang deficiency caused by leucopenia and qi-blood deficiency. The clinical pharmacodynamic test effect of the compound melanterite pill is remarkably improved compared with that of the compound melanterite pill, and the compound melanterite pill is high in bioavailability and free of any toxic and side effects.

Description

Technical Field

[0001] The invention relates to a Chinese medicine prescription composition for warming the kidney and strengthening the marrow, replenishing qi and nourishing yin, generating blood and stopping bleeding and a preparation method thereof, belonging to the technical field of pharmaceuticals. Technical Background

[0002] Compound Zaofan Pills are mainly used to treat aplastic anemia, leukopenia, thrombocytopenia, myelodysplastic syndrome, and bone marrow damage and leukopenia caused by radiotherapy and chemotherapy, which belong to the syndrome of kidney yang deficiency and qi and blood deficiency. Prior art: 1. The prescription and preparation method of Compound Zaofan Pills are disclosed on pages 1321-1322 of the 2020 edition of the Chinese Pharmacopoeia. The prescription does not disclose the dosage, specifically: alum, American ginseng, seahorse, cinnamon, jujube (pitted), walnut kernel. 2. The Chinese Patent Gazette disclosed on May 11, 2016 a patent application entitled "A Chinese medicine composition for warming the kidney and marrow, replenishing qi and nourishing yin, and generating blood and stopping bleeding, and its publication number is CN105560441A. The weight ratio of the raw materials of this invention in Example 1 of the specification is: 25g of alum, 30g of American ginseng, 30g of seahorse, 45g of cinnamon, 60g of pitted jujube, and 30g of walnut kernel. 3. On June 8, 2011, the Chinese Patent Gazette published a patent application entitled "A Compound Soap and Alum Capsule" with a publication number of CN102085253A. In the claims, the weight ratio of the raw materials in claim 1 is: 8-10 parts of soap and alum, 5-6 parts of American ginseng, 3-4 parts of seahorse, 3-4 parts of cinnamon, 6-8 parts of pitted jujube, and 8-10 parts of walnut kernel. The compound soap and alum pill is a product of our company. The above prior art 1 is the pharmacopoeia standard of our compound soap and alum pill, and prior art 2 is the patent for the compound soap and alum pill product applied by our company.

[0003] Compound Zaofan Pills have been used clinically for many years, and have good efficacy in treating aplastic anemia, leukopenia, thrombocytopenia, myelodysplastic syndrome, and bone marrow damage and leukopenia caused by radiotherapy and chemotherapy, which are due to insufficient kidney yang and deficiency of qi and blood, and have been recognized by patients and doctors. In the past 10 years, in order to obtain better product effects, our company has split and combined the prescription of Compound Zaofan Pills on the basis of the prescription of Compound Zaofan Pills, and conducted a lot of basic pharmacodynamics research. It was unexpectedly found that removing the pitted jujube and walnut kernels from the prescription and adjusting the dosage of alum, American ginseng, and seahorse resulted in a new prescription: 30g of alum, 45g of American ginseng, 45g of seahorse, and 45g of cinnamon. The clinical pharmacodynamics experiment of the new prescription of Compound Soap Alum Pill after splitting is remarkable, and it is effective in treating aplastic anemia, leukopenia, thrombocytopenia, myelodysplastic syndrome, bone marrow damage caused by radiotherapy and chemotherapy, leukopenia belonging to kidney yang deficiency and qi and blood deficiency syndrome, without any toxic side effects; we make pills, capsules, tablets and granules according to conventional processes. Summary of the invention

[0004] The purpose of the present invention is to provide a Chinese medicine composition and preparation method for warming the kidney and strengthening the marrow, replenishing qi and nourishing yin, and generating blood and stopping bleeding with significant efficacy. The characteristic is that the weight ratio of each raw material in the Chinese medicine composition of the present invention is:

[0005] 15-35 parts of alum, 35-50 parts of American ginseng, 35-50 parts of seahorse, 35-50 parts of cinnamon.

[0006] The preferred weight ratio of each raw material of the Chinese medicine composition of the present invention is:

[0007] 30 parts of alum, 45 parts of American ginseng, 45 parts of seahorses, 45 parts of cinnamon bars.

[0008] The dosage form of the Chinese medicine composition of the present invention is pills, capsules, tablets or granules, preferably pills.

[0009] The present invention also provides a method for preparing the Chinese medicine composition for warming the kidney and strengthening the marrow, replenishing qi and nourishing yin, and generating blood and stopping bleeding, which is specifically as follows:

[0010] 1. The preparation method of the Chinese medicine composition pills of the present invention:

[0011] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed evenly; 50~60g of refined honey is added to every 100g of powder to make small honey pills, and then coated with activated carbon to obtain pills.

[0012] 2. Preparation method of the Chinese medicine composition capsule of the present invention:

[0013] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, whole, and encapsulated to obtain capsules.

[0014] 3. Preparation method of the Chinese medicine composition tablets of the present invention:

[0015] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and compressed to obtain tablets.

[0016] 4. Preparation method of the Chinese medicine composition granules of the present invention:

[0017] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and bagged to obtain granules.

[0018] The present invention also provides the use of the traditional Chinese medicine composition in preparing a medicine for aplastic anemia.

[0019] Prior art patent search: 1. The Chinese Pharmacopoeia 2020 Edition, Volume 1, pages 1321-1322 discloses the prescription and preparation method of compound alum pills. The prescription does not disclose the dosage, specifically: alum, American ginseng, seahorse, cinnamon, jujube (pitted), walnut kernel. 2. The Chinese Patent Gazette published a patent application entitled "A Chinese medicine composition for warming the kidney and strengthening the marrow, replenishing qi and nourishing yin, and generating blood and stopping bleeding and its preparation method" on May 11, 2016, with a publication number of CN105560441A. The weight ratio of the raw materials of this invention in Example 1 of the specification is: 25g alum, 30g American ginseng, 30g seahorse, 45g cinnamon, 60g pitted jujube, and 30g walnut kernel. 3. On June 8, 2011, the Chinese Patent Gazette published a patent application entitled "A Compound Soap and Alum Capsule" with a publication number of CN102085253A. In the claims, the weight ratio of the raw materials in claim 1 is: 8-10 parts of soap and alum, 5-6 parts of American ginseng, 3-4 parts of seahorse, 3-4 parts of cinnamon, 6-8 parts of pitted jujube, and 8-10 parts of walnut kernel. The compound soap and alum pill is a product of our company. The above prior art 1 is the pharmacopoeia standard of our compound soap and alum pill, and prior art 2 is the patent for the compound soap and alum pill product applied by our company.

[0020] Compound Zaofan Pills have been used clinically for many years, and have good efficacy in treating aplastic anemia, leukopenia, thrombocytopenia, myelodysplastic syndrome, and bone marrow damage and leukopenia caused by radiotherapy and chemotherapy, which are due to insufficient kidney yang and deficiency of qi and blood, and have been recognized by patients and doctors. In the past 10 years, in order to obtain better product effects, our company has split and combined the prescription of Compound Zaofan Pills on the basis of the prescription of Compound Zaofan Pills, and conducted a lot of basic pharmacodynamics research. It was unexpectedly found that removing the pitted jujube and walnut kernels from the prescription and adjusting the dosage of alum, American ginseng, and seahorse resulted in a new prescription: 30g of alum, 45g of American ginseng, 45g of seahorse, and 45g of cinnamon. The clinical pharmacodynamics experiment of the new prescription of Compound Soap Alum Pill after splitting is remarkable, and it is effective in treating aplastic anemia, leukopenia, thrombocytopenia, myelodysplastic syndrome, bone marrow damage caused by radiotherapy and chemotherapy, leukopenia belonging to kidney yang deficiency and qi and blood deficiency syndrome, without any toxic side effects; we make pills, capsules, tablets and granules according to conventional processes.

[0021] The Chinese medicine composition of the invention has the effects of warming the kidney and strengthening the marrow, invigorating qi and nourishing yin, and generating blood and stopping bleeding. The new prescription of the compound soap alum pill after splitting is a prescription ratio obtained through strict pharmacological screening. Compared with the prior art CN105560441A, the invention has significant efficacy in treating aplastic anemia and the like.

[0022] Pharmacodynamics test:

[0023] Pharmacodynamic test of the present invention: Compared with the prior art, the pharmacodynamic test effect of the Chinese medicine composition of the present invention is significantly improved.

[0024] After patent search, the prior art comparative documents are as follows:

[0025] 1. Comparative Document 1: On May 11, 2016, the Chinese Patent Gazette published a patent application entitled “A Chinese medicine composition for warming the kidney and strengthening the marrow, replenishing qi and nourishing yin, and generating blood and stopping bleeding, and its preparation method” with publication number CN105560441A.

[0026] The main pharmacodynamic tests prove that the efficacy of the Chinese medicine composition of the present invention is significantly better than that of the comparative document 1 (CN105560441A). The main pharmacodynamic tests are as follows:

[0027] Preparation of experimental drugs:

[0028] The pill group of the present invention is a pill prepared according to the method of Example 1 of the specific implementation mode of the specification of the present invention.

[0029] Control pill group: pills prepared according to the method of Example 1 (Compound Soap Alum Pills) of the patent application specification of comparative document 1 with publication number CN105560441A.

[0030] Experimental purpose: Through pharmacological experimental studies on the pill group of the present invention and the control pill group in restoring bone marrow function, increasing platelets, hemostasis, improving body immunity and treating aplastic anemia, the pill group of the present invention and the control pill group were compared to observe the strength of their pharmacological effects.

[0031] Experimental methods: The effects of the pill group of the present invention and the control pill group on the prevention and treatment of bone marrow suppression in mice; the effects on the number of peripheral blood platelets in mice; the effects on the bone marrow hematopoietic stem cells acutely damaged by cyclophosphamide in mice; the effects on the coagulation time of warfarin-induced mice; and the effects on the phagocytic function of reticuloendothelial cells in mice.

[0032] 1. Effect on the prevention and treatment of bone marrow suppression in mice

[0033] 1. Animals: Male Balb / c mice, weighing 18-22 g.

[0034] 2. Drugs: There are four experimental groups: normal group, model group, control pill group and pill group of the present invention (alum, American ginseng, hippocampus, cinnamon); the drugs were prepared with distilled water before the experiment and administered by gavage.

[0035] Experimental methods

[0036] Male Balb / c mice weighing 18-22g were taken. After adaptive feeding for 3 days, the chemotherapeutic drug 5-fluorouracil was used to establish the model. 200mg / kg of 5-fluorouracil was injected intraperitoneally once. The success of the bone marrow suppression model was evaluated on the 3rd day after the intraperitoneal injection of 5-fluorouracil. After the model was successfully established, 41 male Balb / c mice were randomly divided into a model group and a pill group of the present invention, with 14 mice in each group, a control pill group of 13 mice, and 13 male Balb / c mice without modeling were taken as a normal group. After grouping, except for the normal group and the model group, the other two groups were gavaged on the first day after the successful modeling. The normal group and the model group were gavaged with equal volumes of physiological saline; the control pill group and the pill group of the present invention were gavaged with 968.8mg crude drug / kg and 484.4mg crude drug / kg, respectively, once a day, for 21 consecutive days.

[0037] Immune organ index test

[0038] After the experiment, the mice were killed by cervical dislocation, and the thymus and spleen were quickly removed, and the excess fat and connective tissue were removed. The thymus index and spleen index were calculated. Experimental results: See Table 1

[0039] Effects on the number of bone marrow cells in myelosuppressed mice

[0040] The femurs of mice in each group were quickly taken and the mouse bone tissue was decalcified. The decalcified femur tissue was fixed in 10% neutral formalin and routinely dehydrated and embedded. The slice thickness was 4μm and routinely dewaxed. Washed with distilled water for 1min. Slices were placed in Perlsstain and stained for 15-30min, and thoroughly rinsed with distilled water for 2-5min. Slices were placed in nuclear fast red staining solution and lightly stained with cell nuclei for 5-10min. Rinse with tap water for 1-5s. Rinse with neutral gum routinely and make transparent. Count the number of nucleated cells in the bone marrow. Experimental results: see Table 2

[0041] Table 1 Thymus and spleen indexes of mice

[0042]

[0043] Compared with the normal group, ## P<0.01, ### P<0.001; compared with the model group, *P<0.05, **P<0.01, ***P<0.001.

[0044] The results showed that compared with the normal group, the mice in the model group had thymus atrophy and compensatory spleen enlargement. After treatment with the control pill group and the pill group of the present invention, thymus atrophy and spleen enlargement were alleviated, and the pill group of the present invention had a significant effect on alleviating thymus atrophy.

[0045] Table 2 Effects on bone marrow cells in myelosuppressed mice

[0046]

[0047]

[0048] Compared with the normal group, ### P<0.001; compared with the model group, **P<0.01, ***P<0.001.

[0049] The results showed that compared with the normal group, the number of bone marrow nucleated cells in the bone marrow suppression model mice decreased significantly (P<0.001). After drug treatment, the number of bone marrow nucleated cells in the mice in the pill group of the present invention and the control pill group recovered significantly.

[0050] 2. Effects on the number of platelets in peripheral blood of mice

[0051] Experimental Materials

[0052] 1. Animals: Male Balb / c mice, weighing 18-22 g.

[0053] 2. Drugs: There are four experimental groups: normal group, model group, control pill group and pill group of the present invention (alum, American ginseng, hippocampus, cinnamon); the drugs were prepared with distilled water before the experiment and administered by gavage.

[0054] Experimental methods

[0055] Male Balb / c mice weighing 18-22g were taken. After 3 days of adaptive feeding, carboplatin injection (10ml:100mg) was injected into the mouse peritoneum to establish the model. Carboplatin was diluted with physiological saline to a concentration of 6.25mg / ml. Each mouse was injected intraperitoneally with 0.2ml / 10g body weight to complete the modeling. 30 male Balb / c mice with successful modeling were randomly divided into a model group, a control pill group and a pill group of the present invention, with 10 mice in each group. Ten male Balb / c mice without modeling were taken as a normal group. After grouping, except for the normal group and the model group, the other two groups were gavaged on the first day after the successful modeling. The normal group and the model group were gavaged with the same volume of physiological saline; the control pill group and the pill group of the present invention were gavaged with 1.0g crude drug / kg, once a day, for 11 consecutive days. One hour after the last administration, 20 μl of blood was accurately drawn from the mouse by using the blood sampling method of the medial canthus venous plexus of the mouse eye with a disposable automatic micropipette to calculate the number of peripheral blood platelets. Experimental results: See Table 3

[0056] Table 3 Effects on mouse peripheral blood platelets

[0057]

[0058] Compared with the model group, *P<0.05, **P<0.01. Compared with the pill group of the present invention, P<0.05.

[0059] The results showed that the control pill group and the pill group of the present invention could significantly increase the number of peripheral blood platelets in mice. There was a significant difference between the control pill group and the model group (P<0.05); there was a very significant difference between the pill group and the model group (P<0.01); there was a significant difference between the control pill group and the pill group of the present invention (P<0.05). It can be seen that the pill group of the present invention has a stronger effect on increasing the number of peripheral blood platelets than the control pill group.

[0060] 3. Effects of cyclophosphamide on bone marrow hematopoietic stem cells in mice with acute injury

[0061] Experimental Materials

[0062] 1. Animals: Male Balb / c mice, weighing 18-22 g.

[0063] 2. Drugs: There are four experimental groups: normal group, model group, control pill group and pill group of the present invention (alum, American ginseng, hippocampus, cinnamon); the drugs were prepared with distilled water before the experiment and administered by gavage.

[0064] Experimental methods

[0065] 40 male Balb / c mice, weighing 18-22g, were randomly divided into 4 groups, 10 mice in each group. Except for the normal group, the other three groups were intraperitoneally injected with 0.2ml / mouse (50mg / kg) of cyclophosphamide, once every other day, for a total of 8 times. The normal group and the model group were gavaged with an equal volume of normal saline on the day after the first administration of cyclophosphamide; the control pill group and the pill group of the present invention were gavaged with 1.0g of crude drug / kg, once a day, for 21 consecutive days. The mice were killed the day after the last administration, and the femurs of the mice were taken according to the conventional method, the femoral bone marrow was flushed, and then the hematopoietic stem cell test was performed. Experimental results: See Table 4

[0066] Table 4 Effects of cyclophosphamide on acute injury of bone marrow hematopoietic stem cells in mice

[0067]

[0068] Compared with the model group, *P<0.05, **P<0.01. Compared with the pill group of the present invention, #P<0.05.

[0069] The results show that the control pill group and the pill group of the present invention can comprehensively improve the proliferation of bone marrow hematopoietic stem cells in mice with acute injury caused by cyclophosphamide. There is a significant difference between the control pill group and the model group (P<0.05); there is a very significant difference between the pill group and the model group (P<0.01); there is a significant difference between the control pill group and the pill group of the present invention (P<0.05). It can be seen that the pill group of the present invention has a stronger effect on improving the proliferation of bone marrow hematopoietic stem cells than the control pill group, indicating that the pill group of the present invention has a stronger effect on treating aplastic anemia than the control pill group.

[0070] 4. Effects on coagulation time in warfarin-treated mice

[0071] Experimental Materials

[0072] 1. Animals: Kunming mice, both male and female, weighing 18-22 g.

[0073] 2. Drugs: There are four experimental groups: normal group, model group, control pill group and pill group of the present invention (alum, American ginseng, hippocampus, cinnamon); the drugs were prepared with distilled water before the experiment and administered by gavage.

[0074] Experimental methods

[0075] 40 Kunming mice, half male and half female, weighing 18-22g, were randomly divided into 4 groups, 10 mice in each group. The normal group and the model group were gavaged with equal volumes of normal saline; the control pill group and the pill group of the present invention were gavaged with 1.0g of crude drug / kg, once a day, for 7 consecutive days. 2h before the last administration, except for the normal group, the rest of the mice were gavaged with 0.05% warfarin normal saline solution 0.1ml / 10g for modeling. 30min after the last gavage of each group of mice, the eyeballs were removed and 0.5ml of blood was collected and dripped into a test tube. The test tube was placed in a water bath at a constant temperature of 37℃, and then the test tube was gently tilted once every 30s at an angle of about 30 degrees to observe whether the blood flows. When the blood in the test tube no longer flows and completely coagulates, the timing is stopped, which is the coagulation time. Experimental results: See Table 5

[0076] Table 5 Effects on coagulation time of warfarin-treated mice

[0077]

[0078] Compared with the model group, *P<0.05, **P<0.01. Compared with the pill group of the present invention, # P<0.05.

[0079] The results showed that the control pill group and the pill group of the present invention can shorten the coagulation time and play a hemostatic role. There was a significant difference between the control pill group and the model group (P<0.05); there was a very significant difference between the pill group of the present invention and the model group (P<0.01); there was a significant difference between the control pill group and the pill group of the present invention (P<0.05). It can be seen that the pill group of the present invention has a stronger hemostatic effect than the control pill group.

[0080] 5. Effects on the phagocytic function of mouse reticuloendothelial cells

[0081] Experimental Materials

[0082] 1. Animals: Kunming mice, both male and female, weighing 18-22 g.

[0083] 2. Drugs: three experimental groups: normal group, control pill group and pill group of the present invention (soap alum, American ginseng, hippocampus, cinnamon);

[0084] The drugs were prepared with distilled water before the experiment and administered by gavage.

[0085] Experimental methods

[0086] Thirty Kunming mice, half male and half female, weighing 18-22g, were randomly divided into three groups, 10 in each group. The normal group was gavaged with an equal volume of physiological saline; the control pill group and the pill group of the present invention were gavaged with 1.0g of crude drug / kg, once a day, for 7 consecutive days. One hour after the last administration, 0.1ml / 10g of body weight of India ink (India ink is prepared with physiological saline at a ratio of 1:5) was injected through the tail vein. After 2min and 10min, 20ul of blood was collected from the mouse's posterior orbital venous plexus, respectively, and absorbed into 2ml of 0.1% Na2CO3 solution. After shaking, the absorbance was measured at a wavelength of 680nm using a spectrophotometer. The mouse clearance index K value was calculated. Experimental results: See Table 6

[0087] Table 6 Effects on the phagocytic function of mouse reticuloendothelial cells

[0088]

[0089] Compared with the normal group, *P<0.05, **P<0.01. Compared with the pill group of the present invention, # P<0.05.

[0090] The results showed that the control pill group and the pill group of the present invention could significantly improve the phagocytic clearance index of mouse reticuloendothelial cells. There was a significant difference between the control pill group and the normal group (P<0.05); there was a very significant difference between the pill group and the normal group (P<0.01); there was a significant difference between the control pill group and the pill group of the present invention (P<0.05). It can be seen that the pill group of the present invention has a stronger effect on improving the body's immunity than the control pill group.

[0091] Experimental results: The pill group of the present invention and the control pill group significantly alleviated thymus atrophy and spleen enlargement; significantly increased the number of nucleated cells in the mouse bone marrow; significantly increased the number of peripheral blood platelets in the mouse; increased the proliferation of hematopoietic stem cells in the acutely damaged bone marrow of the mouse caused by cyclophosphamide, achieving the effect of treating aplastic anemia; significantly shortened the coagulation time and played a hemostatic role; significantly increased the phagocytic clearance index of the mouse reticuloendothelial cells, thereby improving the body's immunity.

[0092] Conclusion: The pill group of the present invention has stronger pharmacological effects than the control pill group in restoring bone marrow function, increasing platelets, hemostasis, improving body immunity and treating aplastic anemia. Therefore, the pill group of the present invention has better clinical efficacy in warming the kidney and strengthening the marrow, replenishing qi and nourishing yin, and generating blood to stop bleeding than the control pill group. DETAILED DESCRIPTION

[0093] Embodiment 1: the preparation of pills of the present invention:

[0094] Formula ratio:

[0095] Alum 30g American ginseng 45g seahorse 45g cinnamon 45g;

[0096] Preparation method:

[0097] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed evenly; 50~60g of refined honey is added to every 100g of powder to make small honey pills, and then coated with activated carbon to obtain pills.

[0098] Example 2: Preparation of capsules of the present invention:

[0099] Formula ratio:

[0100] Alum 30g American ginseng 45g seahorse 45g cinnamon 45g;

[0101] Preparation method:

[0102] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, whole, and encapsulated to obtain capsules.

[0103] Example 3: Preparation of tablets of the present invention:

[0104] Formula ratio:

[0105] Alum 30g American ginseng 45g seahorse 45g cinnamon 45g;

[0106] Preparation method:

[0107] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and compressed to obtain tablets.

[0108] Example 4: Preparation of granules of the present invention:

[0109] Formula ratio:

[0110] Alum 30g American ginseng 45g seahorse 45g cinnamon 45g;

[0111] Preparation method:

[0112] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and bagged to obtain granules.

[0113] Embodiment 5: the preparation of pills of the present invention:

[0114] Formula ratio:

[0115] Alum 15g American ginseng 35g seahorse 35g cinnamon 35g;

[0116] Preparation method:

[0117] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed evenly; 50~60g of refined honey is added to every 100g of powder to make small honey pills, and then coated with activated carbon to obtain pills.

[0118] Example 6: Preparation of capsules of the present invention:

[0119] Formula ratio:

[0120] Alum 15g American ginseng 35g seahorse 35g cinnamon 35g;

[0121] Preparation method:

[0122] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, whole, and encapsulated to obtain capsules.

[0123] Example 7: Preparation of tablets of the present invention:

[0124] Formula ratio:

[0125] Alum 15g American ginseng 35g seahorse 35g cinnamon 35g;

[0126] Preparation method:

[0127] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and compressed to obtain tablets.

[0128] Example 8: Preparation of granules of the present invention:

[0129] Formula ratio:

[0130] Alum 15g American ginseng 35g seahorse 35g cinnamon 35g;

[0131] Preparation method:

[0132] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and bagged to obtain granules.

[0133] Embodiment 9: the preparation of pills of the present invention:

[0134] Formula ratio:

[0135] Alum 35g American ginseng 50g seahorse 50g cinnamon 50g;

[0136] Preparation method:

[0137] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed evenly; 50~60g of refined honey is added to every 100g of powder to make small honey pills, and then coated with activated carbon to obtain pills.

[0138] Example 10: Preparation of capsules of the present invention:

[0139] Formula ratio:

[0140] Alum 35g American ginseng 50g seahorse 50g cinnamon 50g;

[0141] Preparation method:

[0142] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, whole, and encapsulated to obtain capsules.

[0143] Example 11: Preparation of tablets of the present invention:

[0144] Formula ratio:

[0145] Alum 35g American ginseng 50g seahorse 50g cinnamon 50g;

[0146] Preparation method:

[0147] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and compressed to obtain tablets.

[0148] Example 12: Preparation of granules of the present invention:

[0149] Formula ratio:

[0150] Alum 35g American ginseng 50g seahorse 50g cinnamon 50g;

[0151] Preparation method:

[0152] For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and bagged to obtain granules.

Claims

1. A Chinese medicine composition for warming the kidney and strengthening the marrow, replenishing qi and nourishing yin, generating blood and stopping bleeding, characterized in that The weight ratio of each raw material of the Chinese medicine composition is: 15-35 parts of alum, 35-50 parts of American ginseng, 35-50 parts of seahorse, 35-50 parts of cinnamon.

2. The Chinese medicine composition according to claim 1, characterized in that The preferred weight ratio of each raw material in the Chinese medicine composition is: 30 parts of alum, 45 parts of American ginseng, 45 parts of seahorses, 45 parts of cinnamon bars.

3. The Chinese medicine composition according to claim 1 or 2, characterized in that The dosage form of the Chinese medicine composition is pills, capsules, tablets or granules, preferably pills.

4. The method for preparing the Chinese medicine composition according to claim 1, 2 or 3, characterized in that: For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed evenly; 50~60g of refined honey is added to every 100g of powder to make small honey pills, and then coated with activated carbon to obtain pills.

5. The method for preparing the Chinese medicine composition according to claim 1, 2 or 3, characterized in that: For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, whole, and encapsulated to obtain capsules.

6. The method for preparing the Chinese medicine composition according to claim 1, 2 or 3, characterized in that: For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and compressed to obtain tablets.

7. The method for preparing the Chinese medicine composition according to claim 1, 2 or 3, characterized in that: For the above four ingredients, the seahorse is dried at 75℃~80℃ and crushed into fine powder; alum, American ginseng and cinnamon are mixed and crushed into fine powder, mixed with the above seahorse fine powder, sieved and mixed; granulated, dried, granulated and bagged to obtain granules.

8. Use of the Chinese medicine composition according to claim 1 or 2 in the preparation of a medicament for aplastic anemia.

Images